Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-94
AuthorsMichalowska, M. M.
Anton-Rodriguez, Jose M
Karikari, T. K.
Ashton, N. J.
Carter, S. F.
AffiliationWolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
MetadataShow full item record
AbstractAmyloid-beta (Aβ) deposition is common in cognitively unimpaired (CU) elderly >85 years. This study investigated amyloid distribution and evaluated three published in vivo amyloid-PET staging schemes from a cognitively unimpaired (CU) cohort aged 84.9 ± 4.3 years (n = 75). SUV-based principal component analysis (PCA) was applied to 18F-flutemetamol PET data to determine an unbiased regional covariance pattern of tracer uptake across grey matter regions. PET staging schemes were applied to the data and compared to the PCA output. Concentration of p-tau181 was measured in blood plasma. The PCA revealed three distinct components accounting for 91.2% of total SUV variance. PC1 driven by the large common variance of uptake in neocortical and striatal regions was significantly positively correlated with global SUVRs, APOE4 status and p-tau181 concentration. PC2 represented mainly non-specific uptake in typical amyloid-PET reference regions, and PC3 the occipital lobe. Application of the staging schemes demonstrated that the majority of the CU cohort (up to 93%) were classified as having pathological amount and distribution of Aβ. Good correspondence existed between binary (+/-) classification and later amyloid stages, however, substantial differences existed between schemes for low stages with 8-17% of individuals being unstageable, i.e., not following the sequential progression of Aβ deposition. In spite of the difference in staging outcomes there was broad spatial overlap between earlier stages and PC1, most prominently in default mode network regions. This study critically evaluated the utility of in vivo amyloid staging from a single PET scan in CU elderly and found that early amyloid stages could not be consistently classified. The majority of the cohort had pathological Aβ, thus, it remains an open topic what constitutes abnormal brain Aβ in the oldest-old and what is the best method to determine that.
CitationMichalowska MM, Herholz K, Hinz R, Amadi C, McInnes L, Anton-Rodriguez JM, et al. Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-94. Molecular psychiatry. 2022 Jul 20. PubMed PMID: 35858992. Epub 2022/07/21. eng.
- Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.
- Authors: McGrath ER, Beiser AS, O'Donnell A, Yang Q, Ghosh S, Gonzales MM, Himali JJ, Satizabal CL, Johnson KA, Tracy RP, Seshadri S
- Issue date: 2022
- Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
- Authors: Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, Borroni E, Janelidze S, Ohlsson T, Jögi J, Ossenkoppele R, Palmqvist S, Mattsson-Carlgren N, Klein G, Stomrud E, Hansson O
- Issue date: 2022 Feb 1
- Comparison of (11)C-Pittsburgh Compound B and (18)F-Flutemetamol White Matter Binding in PET.
- Authors: Zeydan B, Schwarz CG, Przybelski SA, Lesnick TG, Kremers WK, Senjem ML, Kantarci OH, Min PH, Kemp BJ, Jack CR Jr, Kantarci K, Lowe VJ
- Issue date: 2022 Aug
- Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
- Authors: Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA, 18F-AV-1451-A05 investigators
- Issue date: 2017 Mar 1
- Mesial temporal tau in amyloid-β-negative cognitively normal older persons.
- Authors: Krishnadas N, Doré V, Groot C, Lamb F, Bourgeat P, Burnham SC, Huang K, Goh AMY, Masters CL, Villemagne VL, Rowe CC, AIBL research group
- Issue date: 2022 Apr 8